ライフサイエンスコーパス: osteonecrosis

1 inhibition alone predisposed the animals to osteonecrosis.

2 ical malignancies, are at risk of developing osteonecrosis.

3 t occurring in knees without any evidence of osteonecrosis.

4 control group in a pig model of femoral head osteonecrosis.

5 e dose modification would reduce the risk of osteonecrosis.

6 be a protective factor against alveolar bone osteonecrosis.

7 lymorphisms were associated with symptomatic osteonecrosis.

8 (11.7%) children with GG genotype, developed osteonecrosis.

9 nous microbiota protects against LIP-induced osteonecrosis.

10 genetic variation may contribute to risk of osteonecrosis.

11 dysplasias reminiscent of osteoarthritis and osteonecrosis.

12 intestinal events; malignant conditions; and osteonecrosis.

13 dicted solely by lesion size at diagnosis of osteonecrosis.

14 (range, 0.5 to 8.6 years) after diagnosis of osteonecrosis.

15 and klotho were associated with sickle cell osteonecrosis.

16 tify ALL patients at highest risk to develop osteonecrosis.

17 y, pathogenesis, diagnosis, and treatment of osteonecrosis.

18 the femoral head or, better yet, preventing osteonecrosis.

19 n mice protects against inflammation-induced osteonecrosis.

20 nders the oral microenvironment conducive to osteonecrosis.

21 ents with clinical suspicion of femoral head osteonecrosis.

22 h detection of and determining the extent of osteonecrosis.

23 on of apoptotic osteocytes may contribute to osteonecrosis.

24 oid treatment, and no other risk factors for osteonecrosis.

25 osteoarthritis, inflammatory arthritis, and osteonecrosis.

26 proton-density weighted imaging, similar to osteonecrosis.

27 therapy and in areas not usually affected by osteonecrosis.

28 reases the development of medication-related osteonecrosis.

29 ipants were followed to assess fractures and osteonecrosis.

30 marrow edema syndrome (TBMES) and avascular osteonecrosis.

31 tive therapeutic target for the treatment of osteonecrosis.

32 utual adjustment, no ARV was associated with osteonecrosis.

33 bidities contribute to risk of fractures and osteonecrosis.

34 critical role in the glucocorticoid-induced osteonecrosis.

35 ng induction and experienced excess rates of osteonecrosis.

36 ated with the glomerular filtration rate and osteonecrosis.

37 ide new insights into the pathophysiology of osteonecrosis.

38 emia (ALL) and their major adverse effect is osteonecrosis.

39 tify genetic and nongenetic risk factors for osteonecrosis.

40 ociation may allow interventions to decrease osteonecrosis.

41 idence/1000 PYFU 7.2; 95% CI 6.6-7.7) and 89 osteonecrosis (1.0; 0.8-1.3).

42 nhibit osteoclasts have been associated with osteonecrosis, a condition limited to the jawbone, thus

43 ing the efficacy of ACTH in preventing human osteonecrosis, a devastating complication of glucocortic

44 rrent knowledge of bisphosphonate-associated osteonecrosis, a new oral complication in oncology.

45 To address osteonecrosis, a novel alternate-week schedule of dexame

46 to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed

47 increased prevalence for the development of osteonecrosis among females.

48 fit and was associated with a higher risk of osteonecrosis among participants 10 years and older.

49 hether 12 polymorphisms were associated with osteonecrosis among patients 10 years and older treated

50 Importantly, percentage osteonecrosis and bone exposure were decreased in the ro

51 However, osteonecrosis and bone fracture may affect the accuracy

52 antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity.

53 r bone complications including fractures and osteonecrosis and for reduced or delayed response to enz

54 d, in older children, increased incidence of osteonecrosis and fracture.

55 nd histological assessment showed that total osteonecrosis and inflammatory infiltrate was significan

56 dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic var

57 pensated hypothyroidism in 9 patients (10%), osteonecrosis and moderate osteopenia in 2 patients each

58 ogenous SMOC2 blocks injury-induced jaw bone osteonecrosis and offsets age-induced periodontal decay.

59 There were no cases of incident drug-induced osteonecrosis and only 1 case of femoral shaft fracture

60 ed either to intramedullary hematopoiesis or osteonecrosis and osteomyelitis.

61 ting event in the genesis of steroid-induced osteonecrosis and provides a basis for future investigat

62 ations of HIV and HAART, such as osteopenia, osteonecrosis, and infection continue to be a concern.

63 al skeletal diseases, such as bone fracture, osteonecrosis, and inflammation are characterized by exc

64 performance status scores, incidence of jaw osteonecrosis, and kidney dysfunction did not differ sig

65 ency fracture, complications of pre-existing osteonecrosis, and rapid joint destruction (including bo

66 ral insufficiency fracture, complications of osteonecrosis, and rapid joint destruction, including bo

67 sterol (P = .02) associated with symptomatic osteonecrosis, and severe (grade 3 or 4) osteonecrosis w

68 e-associated hypersensitivity, pancreatitis, osteonecrosis, and thromboembolism were prospectively re

69 dentify individuals who are at high risk for osteonecrosis, and thus allow earlier and more effective

70 ce imaging of both hips was used to diagnose osteonecrosis, and was performed at similar times from t

71 During experimental periodontitis, osteonecrosis area and osteoclast number were significan

72 ifferentiation, were associated with risk of osteonecrosis as well as with lower albumin and higher c

73 ing earlier in the diagnosis of femoral head osteonecrosis, as well as its more widespread use in pat

74 ensitivity to asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, art

75 Osteonecrosis-associated glutamate receptor variants wer

76 1 years, the overall cumulative incidence of osteonecrosis at 5 years was 7.7% (SE 0.9), correlating

77 y-six (92%) of 50 patients with femoral head osteonecrosis at both examinations were placed in the ap

78 No cases of jaw osteonecrosis, atrial fibrillation, or non-healing fract

79 No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractu

80 ral epiphysis (SCFE), and avascular necrosis/osteonecrosis (AVN) in 4598 children and young adults wi

81 en a reduction in the incidence of avascular osteonecrosis (AVN).

82 e increased in acute lymphoblastic leukemia, osteonecrosis became an increasingly frequent complicati

83 ether screening could identify extensive hip osteonecrosis before symptom development.

84 Bisphosphonate-associated osteonecrosis (BON) of the jaw is a growing concern in t

85 antly improved ONFH-induced symptoms such as osteonecrosis, bone loss, reduction in vessel perfusion,

86 osteroid use is an important risk factor for osteonecrosis, but its pathogenesis is likely multifacto

87 es occur, which could prevent morbidities of osteonecrosis by guiding the decisionmaking process for

88 buminuria, leg ulcers, priapism, stroke, and osteonecrosis) by clinical examination, laboratory tests

89 Osteonecrosis can develop spontaneously or after an inva

90 ll disease, clinical complications including osteonecrosis can vary in frequency and severity, presum

91 o the two leading etiologic associations for osteonecrosis: corticosteroids and alcohol.

92 To evaluate whether osteonecrosis could be successfully induced, healing of

93 llowed, documented, and the treatment of the osteonecrosis described.

94 e persisted in the region, and a new site of osteonecrosis developed on the contralateral side of the

95 ay in healing may increase the likelihood of osteonecrosis developing in already-compromised bone.

96 Patterns for TBMES and osteonecrosis did not overlap.

97 n p.Asn409Ser homozygous patients to develop osteonecrosis during treatment.

98 In the most severe cases of osteonecrosis, end-stage lesions consisted of fully occl

99 y therefore have utility in the treatment of osteonecrosis, especially in aged patients.

100 DC-deficient mice were predisposed to osteonecrosis following dental extraction.

101 In mice that developed osteonecrosis following tooth extraction, there was incr

102 Hip osteonecrosis frequently complicates treatment with gluc

103 rs, plesiosaurs, and humans develop dysbaric osteonecrosis from end-artery nitrogen embolism ("the be

104 oral resolution can allow differentiation of osteonecrosis from TBMES in hip and knee joints.

105 Osteonecrosis has been reported to occur occasionally am

106 Prior studies on the genetics of osteonecrosis have focused on patients >/=10 years of ag

107 Putative risk factors for osteonecrosis have included being female, white race, an

108 e receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio = 2.03; P = 3.59 x 10(-7)).

109 ory has developed a model of steroid-induced osteonecrosis in BALBcJ mice which reflects clinically r

110 adults showed a size-related development of osteonecrosis in chevron and rib bone articulations, del

111 first evaluation of genetic risk factors for osteonecrosis in children <10 years.

112 imple dose modification, reduces the risk of osteonecrosis in children and adolescents given intensif

113 To evaluate risk factors for osteonecrosis in human immunodeficiency virus (HIV)-infe

114 The degree of risk for osteonecrosis in patients taking oral bisphosphonates, s

115 ation, oxidant stress, bone metabolism) with osteonecrosis in patients with sickle cell disease.

116 ting clinical joint outcomes of femoral head osteonecrosis in pediatric patients with leukemia or lym

117 may provide insight into the pathogenesis of osteonecrosis in sickle cell disease, help identify indi

118 t predictor of clinical joint outcome of hip osteonecrosis in survivors of pediatric hematologic mali

119 d in hundreds of cases to be associated with osteonecrosis in the jaw.

120 There was one documented case of osteonecrosis in the zoledronic acid group.

121 orphism (rs6092) was associated with risk of osteonecrosis in univariate (P = .002; odds ratio = 2.79

122 subchondral area was found between TBMES and osteonecrosis; in joints with osteonecrosis, this was co

123 elayed intensification significantly reduced osteonecrosis incidence compared with continuous dexamet

124 e race (OR, 11.1; P =.037), host factors for osteonecrosis included the vitamin D receptor FokI start

125 roids remained significantly associated with osteonecrosis, independently of HIV disease stage and pr

126 Studies concerning the treatment of osteonecrosis indicate that most preservative (ie, joint

127 Osteonecrosis is a dose-limiting toxicity in the treatme

128 Osteonecrosis is a severe glucocorticoid-induced complic

129 Bisphosphonate-associated osteonecrosis is characterised by the unexpected appeara

130 Juvenile femoral head osteonecrosis is due to disruption of blood supply which

131 ans, raised a concern that the prevalence of osteonecrosis is increasing.

132 Lesion size of osteonecrosis is the best predictor of clinical joint ou

133 rticoid therapy, screening for extensive hip osteonecrosis is unnecessary because their risk is low a

134 Osteonecrosis joints showed a subchondral area with low

135 7.2%]) of 339 HIV-infected participants had osteonecrosis lesions on magnetic resonance imaging, and

136 e wrist and hand including occult fractures, osteonecrosis, ligamentous and tendon injuries, and entr

137 The future treatment of osteonecrosis may involve genetic or cell-based therapie

138 ate MTT, which was only found in joints with osteonecrosis, mean +/- standard deviation PF was 18.9 m

139 25 patients with and the 39 patients without osteonecrosis (median, 447 days and 443 days, respective

140 Furthermore, in patients with osteonecrosis, Mincle was highly expressed at skeletal s

141 effects, including infection, bone fracture, osteonecrosis, mood and behaviour problems, and myopathy

142 ociated toxicity (hypersensitivity [n = 13]; osteonecrosis [n = 29]; pancreatitis [n = 24]; thromboem

143 Among HIV-infected participants, osteonecrosis occurred more frequently in those who used

144 Osteonecrosis of the capital femoral epiphysis is a sign

145 resonance imaging scans of 80 patients with osteonecrosis of the capital femoral epiphysis.

146 lucocorticoids in which treated mice develop osteonecrosis of the distal femoral epiphysis when admin

147 Osteonecrosis of the femoral head (ONFH) primarily resul

148 se, loss of blood supply results in ischemic osteonecrosis of the femoral head (ONFH).

149 is an important event in steroid-associated osteonecrosis of the femoral head (SONFH).

150 orticotropic hormone (ACTH) protects against osteonecrosis of the femoral head induced by depot methy

151 r, but their effect on risk of fractures and osteonecrosis of the femoral head is less understood.

152 s' disease (Perthes' disease) is a childhood osteonecrosis of the hip for which the disease determina

153 The diagnosis of symptomatic osteonecrosis of the hip in two of the authors' patients

154 e between primary diagnosis and diagnosis of osteonecrosis of the hip was 1.7 years (range, 0.1 to 17

155 Osteonecrosis of the hip, as documented by magnetic reso

156 py for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip.

157 HIV have an unexpectedly high occurrence of osteonecrosis of the hip.

158 el alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozuma

159 (26%) of 526 patients; the most common were osteonecrosis of the jaw (17 [3%]), anaemia (6 [1%]), bo

160 hypophosphataemia (24 [5%] of 526 patients), osteonecrosis of the jaw (17 [3%], pain in extremity (12

161 as associated with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic ac

162 Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a morbid bone disease

163 etio-pathogenesis of bisphosphonate-induced osteonecrosis of the jaw (BONJ).

164 Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) and dental implant fail

165 Bisphosphonate-related osteonecrosis of the jaw (BRONJ) commonly occurs in indi

166 Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) is a feared side effect

167 agent associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ), has been reported as c

168 is is associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ).

169 acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95

170 recent years, new drugs that can also cause osteonecrosis of the jaw (e.g., some monoclonal antibodi

171 ms: atypical femoral fractures (low SOE) and osteonecrosis of the jaw (mostly low SOE).

172 Medication-related osteonecrosis of the jaw (MRONJ) is a detrimental side e

173 Medication-related osteonecrosis of the jaw (MRONJ) is a rare intraoral les

174 Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent but mo

175 Medication-related osteonecrosis of the jaw (MRONJ) is one of the most impo

176 Medication-related osteonecrosis of the jaw (MRONJ) occurs in patients unde

177 oradionecrosis (ORN), and medication-related osteonecrosis of the jaw (MRONJ) with histopathological

178 ors in the development of medication-related osteonecrosis of the jaw (MRONJ), a severe debilitating

179 Medication-related osteonecrosis of the jaw (MRONJ), although initially bel

180 perties but are linked to medication-related osteonecrosis of the jaw (MRONJ), particularly concernin

181 " has been replaced with "medication-related osteonecrosis of the jaw (MRONJ).

182 sphosphonates, can lead to mediation-related osteonecrosis of the jaw (MRONJ).

183 patient [2%]), pain (one patient [2%]), and osteonecrosis of the jaw (one patient [2%]).

184 Osteonecrosis of the jaw (ONJ) affects patients with can

185 The incidence of osteonecrosis of the jaw (ONJ) in the population is low,

186 Osteonecrosis of the jaw (ONJ), a side-effect of bisphos

187 l fracture, atypical femoral fracture (AFF), osteonecrosis of the jaw (ONJ), and esophageal cancer.

188 ta regarding atrial fibrillation, bone pain, osteonecrosis of the jaw (ONJ), atypical fractures, and

189 issues, inappropriate femoral fractures, and osteonecrosis of the jaw (ONJ), the pathophysiological m

190 teriparatide administration in patients with osteonecrosis of the jaw (ONJ).

191 ssociated with the occasional development of osteonecrosis of the jaw (ONJ).

192 ded the guideline to include a discussion of osteonecrosis of the jaw (ONJ).

193 dical benefits seem to outweigh the risk for osteonecrosis of the jaw (ONJ).

194 sion under Adalimumab therapy presented with osteonecrosis of the jaw after suspended oral and intrav

195 tients analysable for safety, three (1%) had osteonecrosis of the jaw and 15 (5%) hypocalcaemia.

196 Osteonecrosis of the jaw and atypical femur fractures ha

197 ents were similar in both groups, except for osteonecrosis of the jaw and hypocalcaemia.

198 or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the

199 Risk factors for osteonecrosis of the jaw and renal impairment should be

200 te proactive adjudication of every potential osteonecrosis of the jaw by an international expert pane

201 Osteonecrosis of the jaw consists of the destruction of

202 33 cases of suspected osteonecrosis of the jaw have been reported, with 26 con

203 d case series described clinical features of osteonecrosis of the jaw in patients with cancer who wer

204 traction could ameliorate medication-related osteonecrosis of the jaw in rats.

205 There was one possible case of osteonecrosis of the jaw in the clodronate group.

206 eons described 104 patients with cancer with osteonecrosis of the jaw in the medical literature and i

207 e conclude that the mechanism of Zol-induced osteonecrosis of the jaw involves disruption of DC immun

208 Osteonecrosis of the jaw occurred at similarly low rates

209 Positively adjudicated osteonecrosis of the jaw occurred in 122 (5%) of 2241 pa

210 Osteonecrosis of the jaw occurred infrequently (2.0%, de

211 33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo.

212 A recommendation regarding osteonecrosis of the jaw was added.

213 Osteonecrosis of the jaw was defined using established c

214 2%] of 697 vs 172 [24%] of 704) but rates of osteonecrosis of the jaw were low in both groups (nine [

215 Seven cases of osteonecrosis of the jaw were reported in the long-term

216 No cases of osteonecrosis of the jaw were reported, and no adverse e

217 y an international expert panel, no cases of osteonecrosis of the jaw were reported.

218 his reason, the term "bisphosphonate-related osteonecrosis of the jaw" has been replaced with "medica

219 Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures

220 28 (5%) patients had positively adjudicated osteonecrosis of the jaw, four (1%) had atypical femur f

221 e dreaded adverse effect of bisphosphonates, osteonecrosis of the jaw, has been widely reported and d

222 res indicate worse disability), incidence of osteonecrosis of the jaw, kidney dysfunction, skeletal m

223 ust be instituted to avoid renal toxicity or osteonecrosis of the jaw.

224 e pathogenesis of the bisphosphonate-induced osteonecrosis of the jaw.

225 ic sites, such as the bisphosphonate-related osteonecrosis of the jaw.

226 zoledronic acid, who unexpectedly developed osteonecrosis of the jaw.

227 isk factor to suffer from medication-related osteonecrosis of the jaw.

228 en patients in the ibandronate arm developed osteonecrosis of the jaw.

229 ons, tumor metastasis and infections such as osteonecrosis of the jaw.

230 the jawbone, thus called medication-related osteonecrosis of the jaw.

231 bserved in the setting of medication-related osteonecrosis of the jaws (MRONJ).

232 Osteonecrosis of the jaws (ONJ) is a rare but severe com

233 Osteonecrosis of the jaws (ONJ), a severe side effect of

234 udies have linked bisphosphonate therapy and osteonecrosis of the jaws (ONJ), but neither causality n

235 Despite these benefits, osteonecrosis of the jaws has recently emerged as a sign

236 Osteonecrosis of the jaws is a recently described advers

237 ing bisphosphonates are at greatest risk for osteonecrosis of the jaws; these patients represent 94%

238 Osteonecrosis of the symphysis pubis was seen in six of

239 Osteonecrosis (ON) is a potentially serious complication

240 ely evaluated the incidence of fractures and osteonecrosis (ON) on two consecutive pediatric ALL prot

241 of developing a serious jaw condition called osteonecrosis (ONJ) increases significantly.

242 2 hips of 91 patients who had no evidence of osteonecrosis or diseases involving bone marrow, no hist

243 dure for the treatment of painful arthritis, osteonecrosis, or fracture.

244 ring from hip pain e.g. from osteoarthritis, osteonecrosis, or hip fractures.

245 nces in the rates of infections, symptomatic osteonecrosis, or other complications during the second

246 n among mice that did versus did not develop osteonecrosis (P < 0.0001); in mice with osteonecrosis,

247 der children, higher cumulative incidence of osteonecrosis (P = .02) and fracture (P = .06).

248 aring surface was evaluated subsequently for osteonecrosis-positive hips on both sets of images.

249 ated with white race, lower nadir CD4, prior osteonecrosis, prior fracture, and prior AIDS.

250 , lower baseline CD4, HCV coinfection, prior osteonecrosis, prior fracture, cardiovascular disease, a

251 rticoid (GC) induced osteoporosis (GIOP) and osteonecrosis remain a significant health issue with few

252 osen based on putative mechanisms underlying osteonecrosis risk.

253 in situ death of isolated segments of bone (osteonecrosis) suggesting that glucocorticoid excess, th

254 , treatments are associated with symptomatic osteonecrosis that disproportionately affects adolescent

255 lop osteonecrosis (P < 0.0001); in mice with osteonecrosis, the associated vessels showed transmural

256 ween TBMES and osteonecrosis; in joints with osteonecrosis, this was comparable to background noise,

257 Four patients developed osteonecrosis; three, insufficiency fractures; and three

258 included allergic reactions to asparaginase, osteonecrosis, thrombosis, and disseminated fungal infec

259 To understand possible linkage of ischemic osteonecrosis to the ER stress, a surgery-induced animal

260 between glutamate receptor polymorphisms and osteonecrosis, using a large discovery cohort and 2 vali

261 y (grade 1-4) versus symptomatic (grade 2-4) osteonecrosis was 71.8% versus 17.6%, respectively.

262 imited and full examinations for presence of osteonecrosis was 98.9% (177 of 179 cases; kappa, 0.97).

263 In conclusion, osteonecrosis was associated with inherited variations n

264 Risk of osteonecrosis was associated with white race, lower nadi

265 The presence of osteonecrosis was determined by two radiologists.

266 Symptomatic osteonecrosis was diagnosed in 143 patients at 377 confi

267 fter tooth extraction, on the development of osteonecrosis was evaluated.

268 No significant difference between TBMES and osteonecrosis was found for MTT (P = .09) and PF (P = .7

269 Extensive asymptomatic osteonecrosis was identified by early screening in 26 pa

270 tic osteonecrosis, and severe (grade 3 or 4) osteonecrosis was linked to poor dexamethasone clearance

271 Joint outcome of osteonecrosis was predicted solely by lesion size at dia

272 TBMES and osteonecrosis were compared statistically by using the M

273 about the risks of bisphosphonate-associated osteonecrosis were disseminated by national regulatory a

274 ineteen joints with TBMES and 17 joints with osteonecrosis were evaluated.

275 wed progression into characteristic signs of osteonecrosis were included in the irreversible group.

276 cally, persistent inflammation and extensive osteonecrosis were seen in group 4.

277 Osteocyte empty lacunae and osteonecrosis were significantly greater in ZA-L.

278 Thirty-seven patients (seventeen osteonecrosis) were included.